Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
Under a Creative Commons license
open access
Keywords
Antiviral
Coronavirus
Pegylated interferon alfa-2b (PEG IFN-α2b)
COVID-19
Cited by (0)
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.